3-硝基邻甲氧基苯胺 | 85-45-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-硝基邻甲氧基苯胺
• 中文别名: 1H-咪唑,2-(1-环己烯-1-基)-4,5-二氢
• 英文名称: 2-methoxy-3-nitroaniline
• 英文别名: 2-Methoxy-3-nitro-anilin
• CAS: 85-45-0
• 化学式: C₇H₈N₂O₃
• 分子量: 168.152
• InChiKey: GVBUHJSIDPIOBZ-UHFFFAOYSA-N

物化性质

• 熔点：
  75-76 °C
• 沸点：
  136-140 °C(Press: 0.5 Torr)
• 密度：
  1.318±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-硝基邻甲氧基苯胺 在 铁粉 、 三乙胺 、 calcium chloride 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 36.0h， 生成
  参考文献：
  名称：

  Melanin-Concentrating Hormone Receptor 1 Antagonists. Synthesis and Structure–Activity Relationships of Novel 3-(Aminomethyl)quinolines

  摘要：

  It was found that 3-(aminomethyl)quinoline derivatives showed high binding affinities for melanin-concentrating hormone receptor 1 (MCHR1) with reduced affinity for serotonin receptor 2c (5-HT2c) when the dihydronaphthalene nucleus of compound 1 (human MCHR1, IC50 = 1.9 nM; human 5-HT2c receptor, IC50 = 0.53 nM) was replaced by other bicyclic core scaffolds. Among the synthesized compounds, 8-methylquinoline derivative 5v especially showed high binding affinity (IC50 = 0.54 nM), potent in vitro antagonistic activity (IC50 = 2.8 nM) for MCHR1, and negligible affinity for 5-HT2c receptor (IC50 > 1000 nM). Oral administration of 5v significantly and dose-dependently suppressed nocturnal food intake in diet-induced obese rats and did not affect food intake in MCHR1-deficient mice. These results and rat pharmacokinetic study findings suggested that compound 5v is a highly potent, orally bioavailable, and centrally acting nonpeptide MCHR1 antagonist.

  DOI：

  10.1021/jm201596h
• 作为产物：
  描述：

  3-硝基水杨酸 在 lithium hydroxide monohydrate 、 叠氮磷酸二苯酯 、 potassium carbonate 、 三氟乙酸 、 三甲胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 丙酮 、 叔丁醇 为溶剂， 反应 30.0h， 生成 3-硝基邻甲氧基苯胺
  参考文献：
  名称：

  Drug Design Targeting T-Cell Factor-Driven Epithelial–Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer

  摘要：

  Metastasis is the cause of 90% of mortality in cancer patients. For metastatic colorectal cancer (mCRC), the standard-of-care drug therapies only palliate the symptoms but are ineffective, evidenced by a low survival rate of similar to 11%. T-cell factor (TCF) transcription is a major driving force in CRC, and we have characterized it to be a master regulator of epithelial-mesenchymal transition (EMT). EMT transforms relatively benign epithelial tumor cells into quasi-mesenchymal or mesenchymal cells that possess cancer stem cell properties, promoting multidrug resistance and metastasis. We have identified topoisomerase II alpha (TOP2A) as a DNA-binding factor required for TCF-transcription. Herein, we describe the design, synthesis, biological evaluation, and in vitro and in vivo pharmacokinetic analysis of TOP2A ATP-competitive inhibitors that prevent TCF-transcription and modulate or reverse EMT in mCRC. Unlike TOP2A poisons, ATP-competitive inhibitors do not damage DNA, potentially limiting adverse effects. This work demonstrates a new therapeutic strategy targeting TOP2A for the treatment of mCRC and potentially other types of cancers.

  DOI：

  10.1021/acs.jmedchem.9b01065

文献信息

• Pyrazole compounds
  申请人：——

  公开号：US20030060453A1

  公开（公告）日：2003-03-27

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。
• 用作CDK7激酶抑制剂的化合物及其应用
  申请人：浙江同源康医药股份有限公司

  公开号：CN112661745A

  公开（公告）日：2021-04-16

  本发明涉及用作CDK7激酶抑制剂的化合物及其应用。具体地，本发明化合物具有式I所示结构，其中各基团和取代基的定义如说明书中所述。本发明的化合物可用作细胞周期蛋白依赖性激酶7(CDK7)的抑制剂，用于增殖性疾病(如癌症)的治疗或预防，尤其是用于调节和治疗与细胞周期蛋白依赖性激酶7(CDK7)的异常活性所导致的相关疾病。
• Mono-nitration of aromatic compounds via nitrate salts
  申请人：Cedilote Miall

  公开号：US20070255057A1

  公开（公告）日：2007-11-01

  A method of nitrating a compound selected from the group consisting of is provided.

  提供了一种从所选化合物中硝化的方法。
• Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular
  申请人：Warner-Lambert Company

  公开号：US05990146A1

  公开（公告）日：1999-11-23

  Benzimidazoles of Formula I below are inhibitors of protein tyrosine kinases, and are useful in treating cellular proliferation. ##STR1## The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.

  下面的I式苯并咪唑是蛋白酪氨酸激酶的抑制剂，对治疗细胞增殖很有用。这些化合物在治疗癌症、动脉粥样硬化、再狭窄和牛皮癣方面特别有效。
• Design, synthesis, and α‐glucosidase‐inhibitory activity of phenoxy‐biscoumarin<i>–N</i>‐phenylacetamide hybrids
  作者：Samira Ansari、Homa Azizian、Keyvan Pedrood、Ali Yavari、Somayeh Mojtabavi、Mohammad A. Faramarzi、Shiva Golshani、Samanesadat Hosseini、Mahmood Biglar、Bagher Larijani、Hossein Rastegar、Haleh Hamedifar、Maryam Mohammadi‐Khanaposhtani、Mohammad Mahdavi

  DOI：10.1002/ardp.202100179

  日期：2021.12

  derivatives (7a–m) were designed based on a molecular hybridization approach as new α-glucosidase inhibitors. These compounds were synthesized with high yields and evaluated in vitro for their inhibitory activity against yeast α-glucosidase. The obtained results revealed that a significant proportion of the synthesized compounds showed considerable α-glucosidase-inhibitory activity in comparison to acarbose

  基于分子杂交方法设计了13 种新的苯氧基-双香豆素-N-苯乙酰胺衍生物 ( 7a - m ) 作为新的 α-葡萄糖苷酶抑制剂。这些化合物以高产率合成，并在体外评估了它们对酵母α-葡萄糖苷酶的抑制活性。所得结果表明，与作为阳性对照的阿卡波糖相比，大部分合成的化合物显示出相当大的α-葡萄糖苷酶抑制活性。代表性地，2-(4-(双(4-羟基-2-氧代-2H-色烯-3-基)甲基)苯氧基) -N- (4-溴苯基)乙酰胺( 7f )，IC 50 = 41.73 ± 0.38 µM 对抗 α-葡萄糖苷酶，比阿卡波糖强约 18 倍（IC 50  = 750.0 ± 10.0 µM）。该化合物是一种竞争性α-葡萄糖苷酶抑制剂。这些化合物的分子建模和动态模拟通过体外实验证实了所获得的结果。化合物7f的药物相似性/ADME/毒性的预测以及与标准药物阿卡波糖的比较表明，新化合物7f在毒性方面可能优于标准药物。